A phase 2/3 multicenter, randomized, open-label study to compare the efficacy and safety of Lenalidomide versus investigator's choice in patients with relapsed or refractory diffuse large B-Cell lymphoma
- Submitting institution
-
University of Southampton
- Unit of assessment
- 1 - Clinical Medicine
- Output identifier
- 52201649
- Type
- D - Journal article
- DOI
-
10.1158/1078-0432.CCR-16-2818
- Title of journal
- Clinical Cancer Research
- Article number
- -
- First page
- 4127
- Volume
- 23
- Issue
- 15
- ISSN
- 1078-0432
- Open access status
- Deposit exception
- Month of publication
- April
- Year of publication
- 2017
- URL
-
-
- Supplementary information
-
-
- Request cross-referral to
- -
- Output has been delayed by COVID-19
- No
- COVID-19 affected output statement
- -
- Forensic science
- No
- Criminology
- No
- Interdisciplinary
- No
- Number of additional authors
-
24
- Research group(s)
-
A - Cancer Sciences
- Citation count
- 69
- Proposed double-weighted
- No
- Reserve for an output with double weighting
- No
- Additional information
- -
- Author contribution statement
- a. The author made a substantial contribution to the conception and design of the study, and to analysis and interpretation of study data
and
b. The author helped draft the output
- Non-English
- No
- English abstract
- -
